Company Overview and News

11
5 Low-Cost Biotech Stocks With High Levels of Growth

3h investorplace
Biotech stocks have a reputation for risk. But not all biotechs are small-cap stocks without any products on the market. And not all biotech stocks act as glorified lottery tickets.
ABT REGN JAZZ CELG SUPN ABT SNY

0
Jazz Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

20h seekingalpha
The following slide deck was published by Jazz Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings call.
JAZZ

25
8 Undervalued Biotech Stocks to Watch

2018-08-20 investorplace - 1
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.
JAZZ EXEL GILD GERN JNJ CELG KMDA ABBV ALNY

0
Pfenex Announces Departure of Chief Medical and Scientific Officer Dr. Hubert Chen

2018-08-16 globenewswire
SAN DIEGO, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Dr. Hubert Chen has resigned from his role as Chief Medical and Scientific Officer, effective September 2, 2018, but will continue to support the company as an advisor. The company is conducting a search for a successor.
JAZZ PFNX

0
Pfenex, Inc (PFNX) CEO Eef Schimmelpennink on Q2 2018 Results - Earnings Call Transcript

2018-08-11 seekingalpha
Greetings, ladies and gentlemen, and welcome to the Pfenex Second Quarter 2018 Results and Business Update Call. [Operator Instructions]
JAZZ PFNX

0
Pfenex Reports Second Quarter Results and Provides Business Update

2018-08-08 globenewswire
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars.
JAZZ PFNX

7
Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat

2018-08-08 zacks
Jazz Pharmaceuticals plc (JAZZ - Free Report) reported adjusted earnings of $3.49 per share for second-quarter 2018, which beat the Zacks Consensus Estimate of $3.22. Earnings rose 36% from the year-ago figure.
SGEN VRTX ELY JAZZ ICFI AERI

4
Jazz Pharmaceuticals Plc (JAZZ) Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Hello and welcome to the Jazz Pharmaceuticals second quarter 2018 earnings conference call. Following an introduction from the company, we will open the call to questions.
WFCNP JAZZ DB MS WFC

0
JAZZ / Jazz Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
Document Table of Contents
JAZZ

0
Spark Therapeutics (ONCE) CEO Jeff Marrazzo on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Good day, ladies and gentlemen, and welcome to the Q2 2018 Spark Therapeutics, Inc. Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference is being recorded.
JAZZ ONCE

1
Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress

2018-08-07 globenewswire - 1
As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show:
JAZZ ONCE

13
Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?

2018-08-06 zacks
We expect Jazz Pharmaceuticals plc (JAZZ - Free Report) to beat expectations when it reports second-quarter results on Aug 7 after market close.
MDGL MKGAF JAZZ MKGAY SRPT BGSF

2
Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

2018-08-06 zacks
Investors are always looking for stocks that are poised to beat at earnings season Jazz Pharmaceuticals plc (JAZZ - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
JAZZ EFR UUUU BGSF FUN

1
Will Wdesk Cloud Platform Drive Workiva's (WK) Q2 Earnings?

2018-08-03 zacks
Workiva Inc. (WK - Free Report) is set to report second-quarter 2018 results on Aug 7. Notably, the company has surpassed the Zacks Consensus Estimate in the trailing four quarters, recording an average positive earnings surprise of 29.24%.
SAP JAZZ CY SAPGF PPL WK

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: G50871105